INHIBIKASE THERAPEUTICS

Basic Information

3350 Riverwood Pkwy
Atlanta, GA, 30339-6451

http://inhibikase.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 828325899
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 2


  1. Novel DFG out inhibitors of Abl-kinases to treat PML

    Amount: $753,121.00

    DESCRIPTION provided by applicant Inhibikase Therapeutics is a clinical stage biopharmaceutical company that has developed a host targeted mechanism of action to treat AIDS related and drug induce ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. System for multidimensional analysis of growth and migration of neurons and neuro

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Inhibikase Therapeutics is a clinical stage, biopharmaceutical company that has developed a host- targeted mechanism of action to treat AIDS-related and drug-induc ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. PML antiviral for AIDS

    Amount: $265,846.00

    DESCRIPTION (provided by applicant): Inhibikase Therapeutics is an early stage biopharmaceutical company developing a novel strategy for treating infectious disease that occurs in AIDS patients. The ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government